Article info
PDFImage of the moment
Horner’s syndrome and apraclonidine eye drops
- Correspondence to Dr Edward Margolin, Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON M5S, Canada; edmargolin{at}gmail.com
Citation
Horner’s syndrome and apraclonidine eye drops
Publication history
- Accepted February 18, 2020
- First published March 17, 2020.
Online issue publication
July 28, 2020
Article Versions
- Previous version (28 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Horner’s syndrome secondary to internal carotid artery occlusion
- Sudden onset of pain in the eye and blurring of vision
- Nasopharyngeal carcinoma presenting as a sixth nerve palsy and Horner’s syndrome
- Neuro-ophthalmology
- The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis
- Eye drop neurology
- Four common diseases causing sudden blindness or death in the eye emergency department
- Confirmation of Horner's syndrome using apraclonidine eye drops
- Diagnosis of Horner's syndrome in dogs and cats
- Neurosarcoidosis with chronic cough and Horner’s syndrome